Delving into the Latest Updates on R-Pharm JSC with Synapse

Overview

Tags

Other Diseases

Skin and Musculoskeletal Diseases

Congenital Disorders

Fusion protein

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	3
Neoplasms	2
Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	5
Fusion protein	1
Monoclonal antibody	1

Top 5 Target	Count

MEK(STE7 family)	1
Opioid receptors	1
M1 receptor x M3 receptor	1
EGFR(Epidermal growth factor receptor erbB1)	1
IL-6(Interleukin-6)	1

The goal of this retrospective registry is to evaluate the efficacy and safety of Refralon®, concentrate for solution for intravenous injection, as chemical cardioversion in patients with paroxysmal and persistent atrial fibrillation and flutter in routine clinical practice. The main questions it aims to answer are:
What is the incidence of sinus rhythm restoration within 6 hours in patients with paroxysmal atrial fibrillation (AF)/atrial flutter (AFL) after the first dose of Refralon®?
What is the incidence of sinus rhythm restoration within 24 hours in patients with persistent AF/AFL after the first dose of Refralon®?

Start Date11 Nov 2022

Sponsor / Collaborator

R-Pharm JSC

100 Clinical Results associated with R-Pharm JSC

Login to view more data

0 Patents (Medical) associated with R-Pharm JSC

Login to view more data

9

Literatures (Medical) associated with R-Pharm JSC

13 Aug 2024·CIRCULATION

Results of International, Double-Blind, Randomized, Placebo-Controlled, Phase IIa Study of Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment–Elevation Myocardial Infarction (STEMI)

Letter

Author: Pereverzeva, Kristina ; Fedash, Andrey ; Staroverov, Ilya ; Novosadov, Vladimir ; Popov, Nikolay ; Meray, Imad ; Golino, Michele ; Rozanov, Denis ; Yakushin, Sergey ; Thomas, Georgia ; Mekhriakov, Sergei ; Turlington, Jeremy S. ; Agirov, Murat ; Lapin, Oleg ; Privalova, Olga ; Bogin, Vlad ; Zubova, Ekaterina ; Kotova, Anastasia ; Pisaryuk, Alexandra ; Selezneva, Natalia ; Seleznev, Sergey ; Talasaz, Azita H. ; Egorova, Alina N. ; Buono, Marco Giuseppe Del ; Zyuryaev, Ilya ; Kalashnikov, Igor ; Lavrovsky, Yan ; Mayorov, Vyacheslav ; Ivanova, Galina ; Abbate, Antonio ; Privalov, Dmitry V. ; Kalimulin, Denis ; Babaeva, Lala ; Pevzner, Dmitry V. ; Cremer, Paul C. ; Kornilov, Egor ; Savelieva, Ekaterina ; Lonchakova, Oxana ; Van Tassell, Benjamin ; Marawan, Amr ; Damonte, Juan Ignacio ; Taylor, Angela ; Nilk, Rostislav ; Duhanina, Ekaterina ; Grishin, Sergey A. ; Pravkina, Ekaterina ; Samsonov, Mikhail Yu ; Shogenov, Zaur ; Markley, Roshanak ; Osmanova, Samra ; Safarian, Vakhtang ; Ponomar, Ekaterina G. ; Yurkovskiy, Andrey

01 Jul 2023·Journal of the American College of Cardiology

Treatment of Idiopathic Recurrent Pericarditis With Goflikicept

Article

Author: Moiseeva, Olga M ; Myachikova, Valentina Yu ; Abbate, Antonio ; Maslyanskiy, Alexey L ; Egorova, Alina N ; Samsonov, Mikhail Yu ; Schedrova, Margarita L ; Lavrovsky, Yan ; Vinogradova, Oksana V ; Grishin, Sergey A ; Gleykina, Ekaterina V

BACKGROUND:

Idiopathic recurrent pericarditis (IRP) is a rare autoinflammatory disease. Interleukin (IL)-1α and IL-1β are the pivotal cytokines in the pathophysiology of acute pericarditis and its recurrence. We created a phase II/III study with a new IL-1 inhibitor-goflikicept in IRP.

OBJECTIVES:

This study sought to evaluate the efficacy and safety of goflikicept treatment in patients with IRP.

METHODS:

We conducted a 2-center open-label study of goflikicept in patients with IRP with and without recurrence at time of enrollment. The study consisted of 4 periods: screening, run-in (open-label treatment period), randomized withdrawal, and follow-up. Patients with clinical response to goflikicept in the run-in period were randomized (1:1) to a placebo-controlled withdrawal period, where the time to first pericarditis recurrence (primary endpoint) was evaluated.

RESULTS:

We enrolled 22 patients, and 20 of these patients were randomized. Reduction of C-reactive protein level accompanied by reduction of chest pain and pericardial effusion compared to baseline was demonstrated during the run-in period. Recurrence of pericarditis occurred in 9 of 10 patients in the placebo group, and there were no recurrence events in goflikicept group within 24 weeks after randomization (P < 0.001). A total of 122 adverse events were reported in 21 patients (95.5%), with no deaths and no new safety signals identified for goflikicept.

CONCLUSIONS:

Treatment with goflikicept prevented recurrences and maintained IRP remission with a favorable risk-benefit ratio. Goflikicept reduced the risk of recurrence compared with placebo. (Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent Pericarditis; NCT04692766).

01 Apr 2017·Journal of clinical psychopharmacology

5-HT6 Receptor Antagonist as an Adjunct Treatment Targeting Residual Symptoms in Patients With Schizophrenia

Article

Author: Potanin, Sergey ; Ivaschenko, Alexander ; Morozova, Margarita ; Lepilkina, Taissia ; Beniashvili, Allan ; Vostokova, Natalia ; Burminskiy, Denis ; Lavrovsky, Yan ; Rupchev, George

Abstract:

Background:

Treating patients who experience residual psychotic symptoms during remission of schizophrenia remains one of the most challenging problems. The mechanisms underlying these symptoms differ from those of acute hallucinations and delusions. 5-HT6 receptor antagonists have been considered promising agents in treatment of residual psychotic symptoms and cognitive dysfunction. The aim of the study was to assess the efficacy of a selective 5-HT6 inhibitor Avisetron in the reduction of residual psychotic symptoms in patients with schizophrenia on stable antipsychotic therapy.

Methods:

Eighty clinically stable outpatient subjects with schizophrenia with residual psychotic symptoms were randomized in a double-blind manner to 6 weeks of Avisetron or placebo at 1:1 ratio. Subjects received 8 mg of Avisetron or placebo on top their stable antipsychotic treatment. Standard clinical scales and cognitive tests were used for endpoint assessment. The primary efficacy endpoint was the mean reduction of total Positive and Negative Syndrome Scale score after 6 weeks of treatment.

Results:

No significant differences in the primary and secondary endpoints were found between the groups. However, based on the subgroup analysis, the significant improvement of total Positive and Negative Syndrome Scale score and residual psychotic symptoms was observed in female patients.

Conclusions:

It was a negative study with unexpected benefits of the drug only in females. We hypothesized that the role of patients' sex can impact the treatment response to serotonergic drugs in general. We suggest a possible synergistic interaction between estrogen and Avisetron by means of modulating the effect of estrogens on the serotonergic system. Future studies targeting the sex-related effects of serotonergic drugs are warranted.

100 Deals associated with R-Pharm JSC

Login to view more data

100 Translational Medicine associated with R-Pharm JSC

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 24 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

1

Phase 3

NDA/BLA

4

2

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Olokizumab ( IL-6 )	Rheumatoid Arthritis More	NDA/BLA
Odelepran ( Opioid receptors )	Alcoholism More	NDA/BLA
Imidafenacin ( M1 receptor x M3 receptor )	Pollakisuria More	NDA/BLA
Goflikicept ( IL-1β )	Familial Mediterranean Fever More	Phase 2
ZD19-0144 ( MEK )	BRAF V600E Mutation-Positive Melanoma More	Preclinical